Human cytomegalovirus (HCMV) is a common yet dangerous infection,
especially for vulnerable groups. In pregnant women, the infection can cause
severe malformations, hearing disorders, and cognitive impairments in newborns.
Among immunocompromised patients, such as organ transplant recipients, HCMV can
lead to severe complications, including organ rejection or systemic infections,
thereby increasing mortality and morbidity.
Developing effective strategies to prevent and treat this infection is
therefore crucial. Among these strategies, the development of a new vaccine
appears promising, although the virus's genetic variability and its ability to
evade the immune system make this task challenging.
This study explores the progress made in developing vaccines against
CMV.
CMV vaccine: progress and challenges
This study examined several CMV vaccine candidates currently in
development, including subunit protein vaccines and mRNA-based vaccines.
Current research highlights the following:
- Several
vaccine candidates have shown promising results, particularly in
preventing congenital infections and reducing post-transplantation
complications.
- mRNA-based
vaccines, such as mRNA-1647, are in advanced stages, with phase III trials
underway and results expected by 2025.
- Vaccine
efficacy varies across trials, but findings suggest they could reduce
mother-to-child transmission and improve the management of post-transplant
infections.
The Future of the CMV vaccine: towards effective prevention
The findings of this study indicate that CMV vaccines, although still
under development, show great potential in preventing congenital infections and
managing complications in transplant recipients.
These advancements represent a
significant opportunity to reduce CMV's public health impact. Future research
must focus on optimizing vaccine formulations and ensuring long-term efficacy,
with a goal of rapid approval for these new treatments.
